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Abstract 
Background: Nowadays, Chlamydia trachomatis is known as a causative agent of 
infertility. Because of, asymptomatic nature of infection, many may suffer from its 
lasting complications such as infertility. This study was performed in Tehran during 
April 2007 to April 2008 to compare the prevalence of Chlamydia trachomatis infec-
tion in fertile and infertile women using ELISA and PCR methods.  
Methods: Overall, 234 infertile and 223 pregnant women, as the fertile group, par-
ticipated in this hospital-based case-control study. After completing an informed 
consent form and the questionnaire, first catch urine and blood sample were obtained 
for PCR and ELISA (IgG, IgM) tests, respectively. Logistic regression analysis was 
used to control possible confounding factors, and determine adjusted odds ratio of 
infertility due to the infection. 
Results: PCR results revealed that 29 (12.4%) of the infertile and 19 (8.5%) of the 
fertile women were positive for C. trachomatis infection (p=0.440). IgG was positive 
in 21 (9.0%) of the infertile and 11 (5.0%) in the fertile group (p=0.093). IgM assays 
identified that 2 (0.9%) of the infertile and 4 (1.8%) of the fertile women were posi-
tive for the micro-organism (p=0.375).  
Conclusion: We found no significant differences among fertile and infertile women 
for Chlamydia trachomatis infection. Nevertheless, molecular techniques which are 
more sensitive, more specific and non-invasive can be used to detect C. trachomatis 
infection.   
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Introduction 
hlamydia trachomatis is the most common 
sexually transmitted bacterial infection (1). 
More than 900.000 infections with C. tra- 
 
chomatis were reported and twice as many were 
 
 
 
 
 
 
unreported in the United States during 2004 (2). 
Vaginal discharge, dysuria, postcoital bleeding, 
intermenstrual bleeding and abdominal pain are 
some of the symptoms that are associated with 
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genital infection with C. trachomatis in women 
(3). This type of bacterial infection may be asymp-
tomatic and delay in its diagnosis may cause 
harmful effects but early detection and appropriate 
treatment can minimize complications in the pa-
tients. Therefore, it is suggested that countries 
provide large scale screening programs for at risk 
patients (4). Screening needs to establish accurate 
and cost-effective tools and laboratory tests. Pol-
ymerase chain reaction (PCR) has been success-
fully used in research studies for the detection of 
Chlamydia trachomatis (CT) DNA. PCR is more 
sensitive than high quality cultures (5). This test is 
expensive and needs more time but a previous 
study suggests that it is a promising method for 
the detection of asymptomatic pelvic infection in 
patients with unexplained infertility (6). Enzyme 
linked immunosorbant assay (ELISA) can detect 
C. trachomatis antibodies as another diagnostic 
tool (7). 
Infection with C. trachomatis can cause urethri-
tis, cervicitis, adnexitis, pelvic inflammatory dis-
ease, or ectopic pregnancy (8) Subfertility (9) and 
infertility (10) in women. Most of these patients 
are asymptomatic and are usually diagnosed with 
the infection when they undergo infertility diag-
nostic procedures (11). In some studies C. tra-
chomatis had greater prevalence in infertile than 
fertile women (12), but their prevalence was 
shown to be the same in other studies (10, 11). 
A previous study reported that the molecular 
prevalence of C. trachomatis was 12.6% in wom-
an in Tehran, the capital of Iran (13), and in an-
other study it was 21.25% in women attending 
Shahid Beheshti Hospital in Isfahan, Iran. Consid-
ering the different prevalence rates of C. tracho-
matis infection in Iran, it is vitally essential to as-
sess the impact of C. trachomatis on the reproduc-
tive health of women (14). Most studies in Iran 
have been limited to case-series but case-control 
studies are so limited. The comparative preva-
lence of Chlamydia is also one of the questions to 
be answered in both fertile and infertile women.  
We compare the prevalence of C. trachomatis 
infection in fertile and infertile women with both 
PCR and ELISA methods in Tehran, Iran, during 
April 2007 to April 2008.  
We undertook this study as there seemed to be 
limited studies on C. trachomatis prevalence in in-
fertile patients in Iran. 
 
 
 
Methods 
Setting: This case-control study was performed at 
the infertility clinic, prenatal clinic and delivery 
room of Vali-e-Asr Hospital, one of the central 
public hospitals of Tehran University of Medical 
Sciences, Tehran, Iran from April 2007 to April 
2008. 
The study was approved by the Ethic Committee 
of Tehran University of Medical Sciences.  
Consecutive sampling was used. After signing an 
informed consent, each participant completed a 
questionnaire on demographic characteristics in-
cluding age, education, occupation, gravidity, con-
traception and previous parities. Information about 
infertility duration, type and etiology of infertility, 
history of abdominal surgeries, abortion or ectopic 
pregnancy were also obtained and a physical ex-
amination was conducted by a gynecologist. Up to 
15 ml of first catch urine (after not voiding urine 
for at least 2 hr) was collected into sterile contain-
ers without preservatives. The specimens were 
transported at room temperature for urine pro-
cessing. Blood samples were obtained by veno-
puncture and the serum was separated by centrifu-
gingation and stored at −20°C. 
Participants: Calculating an odds ratio to 1.7, the 
prevalence of infection was estimated to be 35% 
and 55% in fertile and infertile women, respec-
tively (15). We set the statistical significance level 
at 0.05 and test power at 80% by comparative 
study. We determined the sample size 230 for 
each group of participants. Finally, 234 infertile 
and 224 fertile women could complete the study. 
The first group included infertile women in their 
childbearing age (18 to 49 years). Infertility de-
fined as not being able to achieve pregnancy de-
spite trying at least one year. Those with male 
factor infertility and antibiotic therapy within 30 
days before the assessment were excluded from 
the study. The fertile group included women in 
third trimester of pregnancy admitted to delivery 
room. In this group the exclusion criteria were 
history of infertility, presence of genital tubercu-
losis, and recent antibiotic therapy. 
PCR: Urinary sediments were extracted after 
centrifugation at 5000 rpm for 20 min and frozen 
at −70°C in the laboratory of Children's Medical 
Center affiliated to Tehran University of Medical 
Sciences and they were subsequently transported 
to Avicenna Research Institute for PCR. 
DNA was extracted from the pellets as described 
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by Sambrook and Russel and stored at −20°C 
(16). 
Amplification was performed by PCR method. 
The primer sequences for the amplification of C. 
trachomatis were as follow:  DNA semi-nested or 
S: 5′-CTA-CGC-GTT-TGT-ACT-CCG-TCA-CA 
G-3′, anti-semi-nested or AS: 5′-AAC-TTA-TCC-
TCA-GAA-GTT-TAT-GCA-CTA -3`. PCR was 
performed in 25 µl volume of a master mix con-
taining 1×PCR buffer (10 Mm Tris-HCl, pH=8.3, 
50 mM KCl), 6 mM MgCl2, 0.2 µM of each pri-
mers, 0.6 mM of each dNTPs, 1.0 U Taq polymer-
ase, and 5 µl of the template DNA. Initial denatur-
izing condition of this round was done at 94°C for 
5 min, 37 cycles of 30 s at 94°C, 30 s at 60°C, 30 
s at 72°C and a final extension at 72°C for 5 min. 
The PCR product of 206 bp was electrophoresed 
and visualized on a 1.5% ethidium bromide stained 
agarose gel (16). 
PCR was performed on positive samples for 45 
cycles, and semi-nested PCR on one of the nega-
tive samples to confirm the PCR in each series 
(n=8). The second-round mixture contained the 
same components. Two µl of the first round PCR 
product was used as the template DNA for the 
second-round amplification by using AS2: 5′- 
GGT-AAT-AAT-TTG-CTG-GAT-GGC-3′ primers. 
The second-round amplification condition being 
the same as first-round. The PCR products were 
loaded on a 1.5% gel stained with ethidum bor-
mide for electrophoresis.  
ELISA: C. trachomatis-specific IgG, and IgM 
were determined in serum using Sero CP-IgG,  
-IgM protein ELISA; (EUROIMMUN, Germany), 
according to the manufacturer's instruction. Serum 
was designated as positive if the cut-off index was 
greater than 1.1. ELISA was done in Avicenna 
Research Institute. 
Statistical Analysis: Diagnosis finding (IgG, IgM 
and PCR) were compared between study groups 
using the chi-squared test. Moreover, chi-squared 
was also used to compare C. trachomatis infection 
between the cause and type of infertility test. Lo-
gistic regression was used to show association be-
tween C. trachomatis infection and infertility. For 
this analysis, positive results of each diagnostic 
test (IgG, IgM or PCR) were separately used as 
dependent variables. Sensitivity, specificity, and 
positive and negative predictive values of ELISA 
tests (IgG and IgM) were also determined. The 
analyses were done by SPSS 13 (SPSS Inc, Chi-
cago IL, USA). A p-value less than 0.05 was con-
sidered as statistically significant. 
 
Results 
In this study, we recruited 234 infertile and 223 
fertile women. The mean age of the infertile and 
the fertile groups were 29.85±6.26 and 26.85± 
5.84 years, respectively. Infertility duration of the 
infertile women was 6.33±4.70 years and the 
mean gravidity of pregnant women was 1.85± 
1.08. The percentage of fertile women, with high-
er education (57.4%) was greater than the infertile 
group (8.37%).  
Ovarian (101, 43.2%) and tubal (44, 18.8%) 
causes of infertility were more frequent than other 
causes of infertility. In 159 (67.9 %) women, the 
type of infertility was primary. In the pregnant 
group, 42 (18.8%) women had a previous history 
of abortion and 94 (42.4%) had pervious parities.  
IgG about 21 (9.0%) infertile and 11 (5.0%) fer-
tile participants were positive for IgG (p=0.093). 
IgM was positive in 2 (0.9%) women with infertil-
ity and 4 (1.8%) pregnant women (p=0.375) while 
PCR was positive for C. trachomatis infection in 
29 (12.4%) women with infertility and 19 (8.5%) 
pregnant women (p=0.440). None of these differ-
ences were statistically significant. 
In all the three diagnostic tests, C. trachomatis 
infection was not statistically significant between 
primary and secondary infertility. IgG antibody 
for C. trachomatis infection showed no statistical-
ly significant differences between causes of infer-
tility (p=0.340). However, PCR showed higher 
rates of infection among infertile women with 
ovarian etiology (25.6%, p=0.002) than other eti-
ologies (Table 1).  
After adjusting for possible confounding factors 
in logistic regression analysis C. trachomatis posi-
tivity was not statistically significant in infertile 
against fertile women. The odds ratio was 1.499 
(0.611 to 3.679) for IgG, 0.440 (0.064 to 3.013) 
for IgM and 1.254 (0.613 to 2.562) for PCR. Sen-
Table 1. Positive results of tests based on causes of infertility 
(n=234) 
 
 PCR IgG IgM 
Uterus 1 (4.3%) 3 (12.5%) 0 
Tubal 2 (4.9%) 4 (9.7%) 1 (2.3%) 
Ovarian 22 (25.6%) 4 (4.1%) 1 (1.0%) 
Other 4 (7.0%) 9 (13.8%) 0 
Total 29 (12.4%) 20 (8.7%) 2 (9.0%) 
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sitivity, specificity, positive and negative predic-
tive values, and accuracy for IgG results were 
6.3%, 92.5%, 10.7%, 87.3%, and 81.7%, respec-
tively; for IgM they were 2.1%, 98.5%, 16.7%, 
87.5%, and 86.4%, respectively. 
 
Discussion 
Using different diagnostic methods, we found no 
significant differences between fertile and infertile 
women for C. trachomatis infection. Although 
this finding is compatible with some studies (10, 
11), but some other studies have shown greater 
prevalence for C. trachomatis infection among in-
fertile women and have mentioned it as an infertil-
ity risk factor (12). In case-control studies, group 
selection and control for confounding control can 
explain parts of these differences.  
Prevalence of C. trachomatis in infertile women 
infection based on PCR and serologic detection of 
IgG and IgM respectively was 12.4%, 9.0% and 
0.9%. In developing countries, this rate was re-
ported to be 3.9% by PCR in Jordan (11) and 
23.3% by direct immunoflurescence in Turkey 
(17). About 24% of infertile women had a rate 
lower than 10% in Western Europe. (18). These 
studies showed that about 10% to 30% of infertile 
woman had been infected by C. trachomatis Alt-
hough a rate of about 12.4% in the present study 
is not indicative of a very high rate of infection, 
but it does not mean that the rate of C. tracho-
matis infection is low in Iran. In this study, we 
only evaluated patients in one of Tehran hospitals; 
therefore, the results cannot be generalized. Preva-
lence of C. trachomatis infection may be different 
in other areas in Iran, especially between rural and 
suburban areas. 
These differences seem to be the result of differ-
ences in study settings, such as duration of study, 
socioeconomic status, sample size and diagnostic 
methods. 
Prevalence of C. trachomatis may also vary in 
different groups of infertile women. There are 
some reports that C. trachomatis infection is more 
prevalent in tubal infertility than other types of 
infertility (15). Infection with C. trachomatis can 
cause adnexal adhesions and tubal obstruction 
(19) and it is the most common cause of tubal in-
fertility (20). Therefore, it is rational to deduct 
that the infection is more prevalent in tubal infer-
tility. Tubal assessment is recommended in infer-
tile women with a positive result for C. tracho-
matis antibody (21). Our findings are compatible 
with the study done in northern Iran, which re-
ported the same prevalence for C. trachomatis 
infection in tubal and non-tubal etiologies for in-
fertility (22).   
C. trachomatis infection had the same preva-
lence in primary and secondary causes of infertili-
ty in the present study. This result is in line with 
study performed in Jordan (11); although there 
were also some reports indicating greater preva-
lence for the infection in secondary than primary 
infertility (12, 23). Having the same prevalence in 
different types of infertility, it is probable that C. 
trachomatis may induce infertility by other mech-
anisms than tubal damage, opening the door for 
further investigations.   
An earlier study showed genital C. trachomatis 
is very common (24). Educational programs about 
sexually transmitted diseases is a known way of 
reducing the prevalence of these infections.  
Enzyme-linked immunosorbent assay (ELISA) is 
the first generation of non-cultural tests to diag-
nose chlamydial infection. ELISA uses an en-
zyme-linked monoclonal or polyclonal antibody 
directed at the C. trachomatis lipopolysaccharide 
(25). In the presence of C. trachomatis, the anti-
body binds to LPS, and the linked enzyme induces 
a change in color that can be detected by a spec-
trophotometer. One benefit of ELISA is that spec-
imens do not require refrigeration (25). In the pre-
sent study ELISA showed low sensitivity but ac-
ceptable specificity. Other researchers have also 
reported low sensitivity (26) and adequate speci-
ficity for the test (27). Therefore, ELISA can be 
suggested as a screening test for detecting infec-
tion in patients with infertility. For those who 
have a positive result for C. trachomatis infection 
by this method, confirmatory tests are warranted. 
ELISA is also suggested for subgroups of patients 
with endocervical, urethral, or conjunctival spec-
imens (25).  
The sensitivity of PCR test for detecting C. tra-
chomatis in endocervical samples has ranged from 
51.9% to 96.8% (28−30). PCR has a reported sen-
sitivity of 44.4% to 82.5% (29, 30) for detecting C. 
trachomatis in urine samples from women. Speci-
ficity PCR for C. trachomatis for samples from all 
reproductive organs has been reported to be 98.4% 
to 100% (30).  
All in all, ELISA is recommended as a screening 
test for detecting C. trachomatis infection in indi-
viduals suspected of the infection but a confirma-
tory test needs to be done. Therefore, PCR can be 
used as the confirmatory test for diagnosis of C. 
trachomatis. Although nucleic acid amplification 
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tests (NAATs) need more time and are more ex-
pensive but their accuracy and non-invasiveness 
are noticeable. Additionally, Quantitative PCR is 
more sensitive than PCR because it detects lower 
numbers of microorganisms.  
 
Conclusion 
It seems that C. trachomatis detection and treat-
ment can be useful in infertile women improving 
their ART results. Due to the effects of chlamydia 
infection, tubal involvement and findings of this 
study, Chlamydia screening is highly suggested in 
infertile women before infertility management. Be-
sides, prevention of maternal-fetal complications, 
indicates C. trachomatis screening during preg-
nancy.   
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